作者：
Sarah P,Blagden [1]
;
Lucinda,Billingham [2]
;
Louise C,Brown [3]
;
Sean W,Buckland [4]
;
Alison M,Cooper [5]
;
Stephanie,Ellis [6]
;
Wendy,Fisher [7]
;
Helen,Hughes [8]
;
Debbie A,Keatley [9]
;
Francois M,Maignen [10]
;
Alex,Morozov [11]
;
Will,Navaie [6]
;
Sarah,Pearson [12]
;
Abeer,Shaaban [13]
;
Kirsty,Wydenbach [14]
;
Pamela R,Kearns [15]
;
Experimental Cancer Medicine Centres (ECMC) CID trials working group
作者单位：
Department of Oncology, University of Oxford, Oxford, UK. sarah.blagden@oncology.ox.ac.uk.
[1]
Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Studies, University of Birmingham, Birmingham, UK.
[2]
Medical Research Council (MRC) Clinical Trials Unit, University College London, London, UK.
[3]
Pfizer, Surrey, UK.
[4]
The Association of the British Pharmaceutical Industry (ABPI), London, UK.
[5]
Health Research Authority, London, UK.
[6]
Wendy Fisher Consulting (WFC) Ltd, London, UK.
[7]
Cardiff and Vale University Health Board, Cardiff, UK.
[8]
Independent Cancer Patients' Voice, National Cancer Research Institute (NCRI), London, UK.
[9]
National Institute for Health and Care Excellence (NICE), London, UK.
[10]
Pfizer, New York, USA.
[11]
Oncology Clinical Trials Office, University of Oxford, Oxford, UK.
[12]
Queen Elizabeth Hospital Birmingham and the University of Birmingham, Birmingham, UK.
[13]
Medicines and Healthcare products Regulatory Agency (MHRA), London, UK.
[14]
Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Studies, University of Birmingham, Birmingham, UK.;National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Cancer and Genomic Studies, University of Birmingham, Birmingham, UK.
[15]
DOI
10.1038/s41416-019-0653-9
PMID
31907370
发布时间
2024-09-07
换一批
换一批
